On November 19, 2021, January 4, 2022, and February 25, 2022, the Pharmacy and Therapeutics (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross. These policies were developed, revised, or reviewed to support clinical coding edits.

 

Visit Clinical Criteria to search for specific policies. If you have questions or would like additional information, use this email.

 

Please see the explanation/definition for each category of Clinical Criteria below:

  • New: newly published criteria
  • Revised: addition or removal of medical necessity requirements, new document number
  • Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

 

Please share this notice with other members of your practice and office staff.

 

Note: The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.

 

Effective date

Document number

Clinical Criteria title

New or revised

August 8, 2022

*ING-CC-0211

Kimmtrak (tebentafusp-tebn)

New

August 8, 2022

*ING-CC-0210

Enjaymo (sutimlimab-jome)

New

August 8, 2022

*ING-CC-0213

Voxzogo (vosoritide)

New

August 8, 2022

*ING-CC-0212

Tezspire (tezepelumab-ekko)

New

August 8, 2022

*ING-CC-0086

Spravato (esketamine) Nasal Spray

Revised

August 8, 2022

ING-CC-0157

Padcev (enfortumab vedotin)

Revised

August 8, 2022

ING-CC-0125

Opdivo (nivolumab)

Revised

August 8, 2022

ING-CC-0119

Yervoy (ipilimumab)

Revised

August 8, 2022

*ING-CC-0099

Abraxane (paclitaxel, protein bound)

Revised

August 8, 2022

ING-CC-0120

Kyprolis (carfilzomib)

Revised

August 8, 2022

ING-CC-0126

Blincyto (blinatumomab)

Revised

August 8, 2022

ING-CC-0129

Bavencio (avelumab)

Revised

August 8, 2022

*ING-CC-0090

Ixempra (ixabepilone)

Revised

August 8, 2022

ING-CC-0110

Perjeta (pertuzumab)

Revised

August 8, 2022

ING-CC-0115

Kadcyla (ado-trastuzumab)

Revised

August 8, 2022

ING-CC-0108

Halaven (eribulin)

Revised

August 8, 2022

*ING-CC-0033

Xolair (omalizumab)

Revised

August 8, 2022

*ING-CC-0043

Monoclonal Antibodies to Interleukin-5

Revised

August 8, 2022

ING-CC-0038

Human Parathyroid Hormone Agents

Revised

August 8, 2022

*ING-CC-0186

Margenza (margetuximab-cmkb)

Revised

August 8, 2022

*ING-CC-0124

Keytruda (pembrolizumab)

Revised

August 8, 2022

*ING-CC-0078

Orencia (abatacept)

Revised

August 8, 2022

ING-CC-0050

Monoclonal Antibodies to Interleukin-23

Revised

August 8, 2022

ING-CC-0042

Monoclonal Antibodies to Interleukin-17

Revised

August 8, 2022

*ING-CC-0029

Dupixent (dupilumab)

Revised

August 8, 2022

*ING-CC-0208

Adbry (tralokinumab)

Revised

August 8, 2022

*ING-CC-0209

Leqvio (inclisiran)

Revised

August 8, 2022

*ING-CC-0166

Trastuzumab Agents

Revised

August 8, 2022

*ING-CC-0107

Bevacizumab for Non-ophthalmologic Indications

Revised


Email is the quickest and most direct way to receive important information from Anthem Blue Cross. To start receiving email from us (including some sent in lieu of fax or mail), submit your information via our online form (https://bit.ly/3lLgko8).


ACA-NU-0437-22



Featured In:
June 2022 Anthem Blue Cross Provider News - California